Elicio Therapeutics Stock Today
| ELTX Stock | 8.12 0.28 3.57% |
PerformanceGood
| Odds Of DistressAverage
|
Elicio Therapeutics is trading at 8.12 as of the 20th of March 2025; that is 3.57% up since the beginning of the trading day. The stock's open price was 7.84. Elicio Therapeutics has 54 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Elicio Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 15.86 M outstanding shares of which 139.86 K shares are currently shorted by private and institutional investors with about 2.83 trading days to cover. More on Elicio Therapeutics
Moving against Elicio Stock
Elicio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CEO | Robert Connelly | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsElicio Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Elicio Therapeutics' financial leverage. It provides some insight into what part of Elicio Therapeutics' total assets is financed by creditors.
| |||||
Elicio Therapeutics (ELTX) is traded on NASDAQ Exchange in USA. It is located in 451 D Street, Boston, MA, United States, 02210 and employs 32 people. Elicio Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 126.42 M. Elicio Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 15.86 M outstanding shares of which 139.86 K shares are currently shorted by private and institutional investors with about 2.83 trading days to cover.
Elicio Therapeutics generates negative cash flow from operations
Check Elicio Therapeutics Probability Of Bankruptcy
Ownership AllocationElicio Therapeutics holds a total of 15.86 Million outstanding shares. Elicio Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Elicio Ownership Details
Elicio Therapeutics Historical Income Statement
Elicio Stock Against Markets
Elicio Therapeutics Corporate Management
| Joy Seymour | VP Affairs | Profile | |
| Esther Welkowsky | Senior Development | Profile | |
| Peter DeMuth | Chief Officer | Profile | |
| Michael DiVecchia | Senior Resources | Profile | |
| Megan Filoon | Secretary Counsel | Profile | |
| Brian Piekos | Chief Officer | Profile |
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.